A shift towards value-based healthcare (VBC) has prompted industry participants to collaborate on innovative approaches to deliver improved outcomes in a more cost-effective manner. To reset perceptions and realize opportunities in VBC, manufacturers need to be proactive, establishing programs and partnerships that demonstrate outcome benefits and clearly define and articulate the value they add to the healthcare system.
To read more, click the link below.
World Orphan Drug Congress Europe 2024 Review: 3 Themes for sustainable and equitable access to medicines for RD patients
This year’s European World Orphan Drug Congress, attended by CRA’s Bhavesh Patel, Michele Pistollato, Charlotte Poon, Owen Male and Clara Zacharko in...